

## Special Issue

# Synthesis of Novel Antimicrobial Agents, 2nd Edition

### Message from the Guest Editor

The first volume of the Special Issue "Synthesis of Novel Antimicrobial Agents" was published in 2022. It was a successful issue with several published papers and has encouraged us to open a second volume with the same topic. As a continuation of the Special Issue published in 2022, in this second volume, we also invite researchers to submit manuscripts about the Synthesis of Novel Antimicrobial Agents. Studies about their bio-evaluation and further studies will also be considered. Manuscripts on *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter* spp., *Staphylococcus* spp., *Acinetobacter* spp., *Pseudomonas* spp., and *Enterococcus* spp. are especially encouraged.

### Guest Editor

Dr. Sidharth Chopra

Division of Molecular Microbiology and Immunology, CSIR-Central Drug Research Institute, Sector 10, Janakipuram Extension, Sitapur Road, Lucknow 226031, Uttar Pradesh, India

### Deadline for manuscript submissions

closed (31 July 2024)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/195573](https://mdpi.com/si/195573)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)